Molecule

S1193 

Research Area: Immunology, Neurological Disease
Biological Activity:
Thalidomide was introduced as a sedative drug in the late 1950s. However, it was withdrawn due to a teratogenic effect on fetal development. Thalidomide binds to inactivate the protein cereblon, which is important to limb formation. [1]There is now a growing clinical interest in thalidomide since it is introduced as an immunomodulatory agent used primarily, combined with dexamethasone, to treat multiple myeloma. The combination of thalidomide and dexamethasone, often in combination with melphalan, is now one of the most common regimens for patients with newly diagnosed multiple myeloma, with an improved response rate of up to 60-70%. [1]

02158753 

Purity: 99% Inhibits HIV-I replication, FGF-induced angiogenesis, and α-TNF biosynthesis.

Thalidomide 

T144 

Biochem/physiol Actions
(±)-Thalidomide selectively inhibits biosynthesis of tumor necrosis factor α (TNF-α); inhibitor of angiogenesis; immunosuppressive; sedative; teratogen.
Other Notes
Tandem Mass Spectrometry data independently generated by Scripps Center for Metabolomics is available to view or download in PDF. T144.pdf Tested metabolites are featured on Scripps Center for Metabolomics METLIN Metabolite Database. To learn more, visit sigma.com/metlin.

T338850 

Inhibits FGF-induced angiogenesis. Inhibits replication of human immunodeficiency virus type 1. Teratogenic sedative. There is now a growing clinical interest in Thalidomide, and it is introduced as an immunomodulatory agent used primarily in combinatio

CHEBI:74947 

A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.